The clinical management of Chronic Hepatitis B (CHB) and Chronic Hepatitis C (CHC) focuses on viral suppression or eradication, accurate staging and regression tracking of liver fibrosis, and structured long-term monitoring to prevent hepatocellular carcinoma (HCC) and end-stage liver disease.

1. Antiviral Interventions & Efficacy

• Treatment Goal: Viral eradication, defined as Sustained Virologic Response (SVR12) (undetectable HCV RNA 12 weeks post-treatment), which correlates with a >90% reduction in liver-related mortality and HCC risk.
• First-Line Regimens: Pan-genotypic Direct-Acting Antiviral (DAA) combinations administered for 8–12 weeks yield SVR12 rates exceeding 95–98%:

• Glecaprevir / Pibrentasvir (GLE/PIB): NS3/4A protease inhibitor + NS5A inhibitor (pangenotypic, 8 weeks in treatment-naive patients without cirrhosis or with compensated cirrhosis).
• Sofosbuvir / Velpatasvir (SOF/VEL): NS5B polymerase inhibitor + NS5A inhibitor (pangenotypic, 12 weeks).
• Sofosbuvir / Velpatasvir / Voxilaprevir (SOF/VEL/VOX): Used primarily as a 12-week salvage regimen for patients who failed prior DAA therapy containing an NS5A inhibitor.

• Special Considerations:

• Decompensated Cirrhosis (Child-Pugh B/C): Protease inhibitors (Glecaprevir, Voxilaprevir) are contraindicated due to hepatotoxicity risks. Treatment utilizes SOF/VEL + Ribavirin (or SOF/VEL for 24 weeks if ribavirin-ineligible).
• Renal Impairment: GLE/PIB and SOF-based regimens are safe across all stages of chronic kidney disease, including hemodialysis.

• Treatment Goal: Long-term viral suppression (\text{HBV DNA} < 20\text{ IU/mL}), ALT normalization, and prevention of disease progression. Complete cure (loss of cccDNA) remains rare; functional cure (\text{HBsAg} loss with or without anti-HBs seroconversion) occurs in <1\text{--}3\% of nucleos(t)ide analogue (NA)-treated patients.
• First-Line Nucleos(t)ide Analogues (NAs): High barrier to resistance agents given as long-term oral monotherapy:

• Tenofovir Alafenamide (TAF): Targeted prodrug of tenofovir with equivalent viral efficacy to TDF but improved renal and bone safety profiles.
• Tenofovir Disoproxil Fumarate (TDF): Potent suppression; requires renal and bone mineral density monitoring. Preferred in pregnancy.
• Entecavir (ETV): Highly effective in NA-naive patients; requires dose adjustment for \text{eGFR} < 50\text{ mL/min}. Contraindicated or discouraged if prior lamivudine resistance exists.

• Treatment Eligibility Criteria: Recent international guidelines (WHO, CASL/AMMI, AASLD updates) emphasize expanding eligibility:

• Treatment is mandatory for all patients with compensated or decompensated cirrhosis, regardless of ALT or HBV DNA levels.
• Non-cirrhotic patients: Eligible if \text{HBV DNA} > 2,000\text{ IU/mL} and \text{ALT} > \text{Upper Limit of Normal (ULN)}, or if significant fibrosis (\ge \text{F2}) is present.
• Expanded criteria allow treatment for patients >40 years with elevated HBV DNA despite normal ALT, or those with a family history of HCC, co-infections (HIV, HDV, HCV), or extrahepatic manifestations.

2. Liver Fibrosis Scoring & Staging

Accurate staging guides the urgency of treatment, surveillance intervals, and prognostic counseling.

• APRI (AST-to-Platelet Ratio Index): \text{APRI} = \frac{(\text{AST} / \text{AST Upper Limit of Normal})}{\text{Platelet Count } (10^9/\text{L})} \times 100

• Cutoffs: <0.5 rules out significant fibrosis; >1.5 indicates significant fibrosis (\ge \text{F2}); >2.0 suggests cirrhosis (\text{F4}).

• FIB-4 Index (Fibrosis-4 Index): \text{FIB-4} = \frac{\text{Age (years)} \times \text{AST (U/L)}}{\text{Platelet Count } (10^9/\text{L}) \times \sqrt{\text{ALT (U/L)}}}

• Cutoffs: <1.45 has a high negative predictive value for advanced fibrosis; >3.25 indicates advanced fibrosis/cirrhosis (\text{F3–F4}).

• Transient Elastography (VCTE / FibroScan): Measures Liver Stiffness Measurement (LSM) in kilopascals (\text{kPa}).

• HBV Thresholds: <6.0\text{ kPa} excludes significant fibrosis; >8.0\text{--}9.0\text{ kPa} indicates significant fibrosis (\ge \text{F2}); >11.0\text{--}12.0\text{ kPa} suggests cirrhosis (\text{F4}).
• HCV Thresholds: <7.0\text{ kPa} rules out advanced fibrosis; >9.5\text{ kPa} indicates \ge \text{F3}; >12.5\text{ kPa} suggests cirrhosis (\text{F4}).

• Shear Wave Elastography (2D-SWE / pSWE): Integrated into standard ultrasound systems; yields comparable diagnostic accuracy to VCTE for staging \ge \text{F2} and \text{F4}.

• Indication: Reserved for indeterminate non-invasive test results, discordant serum/elastography markers, or suspect co-existing pathologies (e.g., MASH, autoimmune hepatitis).
• Scoring Systems: METAVIR (\text{F0} = \text{no fibrosis} to \text{F4} = \text{cirrhosis}) or Ishak scale (0\text{--}6).

3. Clinical & Laboratory Monitoring Protocols

• Pre-Treatment Phase: Establish baseline metrics including HCV RNA quantitative levels, genotype (if non-pangenotypic regimens are evaluated), non-invasive fibrosis scores (FIB-4 or VCTE), liver function panels, eGFR, and co-infection screens (HIV/HBV).
• On-Treatment Monitoring: Evaluate treatment adherence and check baseline liver function tests at Week 4 if clinical concerns or elevated baseline ALT exist, concluding with an end-of-treatment review.
• Post-Treatment Evaluation: Perform a quantitative HCV RNA test at 12 weeks post-therapy to confirm Sustained Virologic Response (SVR12).
• Post-SVR Care (Non-Cirrhotic, \le \text{F2}): Patients with baseline non-significant fibrosis and normalized liver enzymes require no further routine viral or hepatic monitoring and can be safely discharged.
• Post-SVR Care (\ge \text{F3} or Cirrhosis): Maintain lifetime bi-annual abdominal ultrasound surveillance (with or without Alpha-Fetoprotein) for HCC detection. Schedule baseline upper GI endoscopy to screen for esophageal varices in clinical cirrhosis per Baveno VII guidelines.

• Untreated / Low-Risk Cohorts: Conduct liver function tests, serum HBV DNA quantitations, and non-invasive fibrosis assessments (FIB-4 or VCTE) every 6 to 12 months.
• Patients on Antiviral Therapy (NAs): Monitor serum HBV DNA every 3 to 6 months to confirm virologic suppression and compliance. Assess renal function (eGFR) and serum phosphate levels (for TDF) every 3 to 6 months. Measure quantitative HBsAg annually to track potential functional cure progress.
• HCC Surveillance Protocol: Execute abdominal ultrasound imaging (with or without serum AFP) every 6 months for designated high-risk groups:

1. All individuals with established cirrhosis (\text{F4}).
2. Patients with elevated risk scores (PAGE-B \ge 10 or mPAGE-B \ge 9).
3. Individuals of African or Black origin over 20 years of age.
4. Asian males over 40 years of age and Asian females over 50 years of age.
5. Any patient with a documented family history of hepatocellular carcinoma.

Summary of Key Clinical Priorities

• HCV: Rapidly assess with non-invasive tests (FIB-4/FibroScan), initiate pangenotypic DAAs (GLE/PIB or SOF/VEL), confirm SVR12, and maintain lifetime bi-annual HCC surveillance for any patient with pre-existing advanced fibrosis (\ge \text{F3}) or cirrhosis despite viral cure.
• HBV: Continuously evaluate viral load, ALT, and fibrosis progression. Initiate early NA monotherapy (TAF, TDF, or ETV) to prevent clinical decompensation, monitor renal/bone safety parameters, and strictly adhere to 6-month HCC ultrasound screening protocols for all elevated-risk categories.

10 Frequently Asked Questions (FAQs)

A functional cure in Chronic Hepatitis B is defined as the sustained loss of serum HBsAg with or without anti-HBs seroconversion, alongside undetectable HBV DNA. It remains difficult to achieve with current nucleos(t)ide analogues (NAs), occurring in less than 1\text{--}3\% of treated patients.

Protease inhibitors (such as Glecaprevir and Voxilaprevir) are primarily metabolized by the liver. In patients with Child-Pugh B or C decompensated cirrhosis, significantly impaired hepatic clearance leads to elevated drug concentrations, which carries a severe risk of hepatotoxicity and further clinical decompensation.

TAF is a targeted prodrug that delivers the active metabolite (tenofovir diphosphate) directly into hepatocytes more efficiently at a lower dose than TDF. This results in significantly lower plasma tenofovir levels, providing equivalent viral suppression while reducing the risk of renal toxicity and bone mineral density loss.

Yes. Sustained Virologic Response (SVR12)—defined as undetectable HCV RNA 12 weeks after completing Direct-Acting Antiviral (DAA) therapy—is considered a virologic cure, as late relapse rates beyond this point are extremely low (<1\%).

Routine HCC screening is only necessary if the patient had advanced fibrosis (\ge \text{F3}) or established cirrhosis (\text{F4}) prior to starting DAA therapy. Patients with mild-to-moderate fibrosis (\le \text{F2}) who achieve SVR12 do not require long-term bi-annual HCC surveillance.

FIB-4 and APRI are validated, non-invasive serological scoring models calculated from standard blood tests (AST, ALT, Age, Platelets). They are used as initial screening tools to rule out or identify significant fibrosis (\ge \text{F2}) or advanced cirrhosis (\text{F4}), reducing the need for routine liver biopsies.

Entecavir shares a similar resistance pathway with Lamivudine. If a patient has a history of Lamivudine resistance, the genetic threshold for developing Entecavir resistance drops substantially, making Entecavir ineffective over time. Tenofovir formulations (TDF or TAF) are preferred in this setting.

High-risk Chronic Hepatitis B cohorts (including all cirrhotic patients, older Asian individuals, Black patients over 20, and those with high PAGE-B risk scores) must undergo abdominal ultrasound screening with or without Alpha-Fetoprotein (AFP) testing every 6 months.

Generally, no. Nucleos(t)ide analogues suppress viral replication but do not eliminate the intrahepatic cccDNA pool. Discontinuing treatment without reaching explicit stopping criteria (such as confirmed HBsAg loss) can trigger severe viral rebound, acute ALT flares, and life-threatening liver decompensation.

On Transient Elastography (FibroScan), a Liver Stiffness Measurement (LSM) suggesting cirrhosis (\text{F4}) is typically \ge 11.0\text{--}12.0\text{ kPa} for Chronic Hepatitis B and \ge 12.5\text{ kPa} for Chronic Hepatitis C.